News | Lung Cancer | March 28, 2017

Biomarker Blood Test Shows Lung Cancer Recurrence Months Before CT Scans

Prospective clinical trial demonstrates that testing for CTCs reveals lung cancer recurrence an average of six months earlier than conventional scans

lung cancer recurrence, biomarker blood test, CT scans, 2017 Multidisciplinary Thoracic Cancers Symposium, clinical study

March 28, 2017 — Results from a prospective clinical trial showed a blood test looking at specific biomarkers was able to detect lung cancer recurrences an average of six months before conventional imaging methods found evidence of recurrence. In the largest prospective clinical trial to date of circulating tumor cells (CTC) as biomarkers for locally advanced lung cancer, the findings indicate that blood tests potentially can be used in conjunction with computed tomography (CT) and positron emission tomography (PET)/CT scans to guide personalized treatment planning for patients with non-small cell lung cancer (NSCLC). The study was presented at the 2017 Multidisciplinary Thoracic Cancers Symposium, March 16-18 in San Diego.

Lung cancer is known for its aggressive nature and ability to spread throughout a patient's body. Cancer cells that enter the blood stream are known as circulating tumor cells (CTCs). While the current standard of care following treatment for locally advanced NSCLC is for patients to get surveillance CT or PET/CT scans to monitor for cancer recurrence, new tests can track elevated CTC counts through a simple blood test, allowing for more frequent and less invasive follow-up. Other biomarkers, such as circulating tumor DNA (ctDNA), also have been studied in lung cancer, although ctDNA trials have been largely restricted to advanced (i.e., metastatic) disease, which is not amenable to curative treatments. By using CTC counts as a biomarker for recurrence in localized disease, treatment teams may be able to diagnose recurrence significantly earlier than they could with imaging scans alone.

"The additional lead time afforded by an earlier diagnosis may enable doctors to better tailor alternative and salvage treatments to improve their patients' outcomes and quality of life. Earlier detection of recurrence may even translate into an increased likelihood of curing these patients when their tumor burden is lowest and thus more likely to respond to therapy," said Chimbu Chinniah, lead author of the study and a research fellow in radiation oncology in the Perelman School of Medicine at the University of Pennsylvania in Philadelphia.

A total of 48 patients with stage II-III locally advanced NSCLC were enrolled in the prospective clinical trial. All patients were treated with concurrent chemoradiation. Blood samples were obtained before treatment, during treatment (at weeks 2, 4 and 6) and following treatment (at months 1, 3, 6, 12, 18 and 24). Circulating tumor cells were identified by analyzing the samples with an adenoviral probe that detects elevated activity of a specific enzyme that is produced when cancer cells replicate. Surveillance scans with CT or PET/CT imaging were performed at three-month intervals.

Patients ranged in age from 31 to 84, with a median age of 66 years. No patient had a history of prior malignancy. Researchers also assessed patient gender (54 percent male), race (69 percent Caucasian, 21 percent African American), smoking status (77 percent former, 21 percet current), histology (48 percent squamous cell carcinoma, 46 percent adenocarcinoma) and primary tumor size (median 3.7 centimeters).

At a median follow-up of 10.9 months following treatment for locally advanced NSCLC, nearly half (46 percent) of the patients experienced recurrence or progression, as detected by conventional surveillance scans and biopsies. The median time to recurrence was 7.6 months, with a range of 1.3 to 32 months. Blood samples were obtained following chemoradiation therapy for 20 of the 22 recurrent patients.

Fifteen of these 20 patients had elevated CTC counts following treatment, with a median lead time of 4.7 months and a range of 1.2 months to one year. Of these 15 patients, two-thirds demonstrated a rise in CTC counts an average of six months before PET/CT or CT scans detected the recurrence. For many patients, CTC levels were negative immediately following treatment but rose subsequently in the months following treatment. While most of these CTC level rises occurred before disease recurrence was identified on imaging, four of the 20 patients experienced recurrences that were detected with imaging before elevated CTC levels indicated the disease had returned.

"The future use of circulating tumor cells as a diagnostic and prognostic tool for localized NSCLC looks promising. Although imaging remains the cornerstone of post-treatment surveillance for patients, blood tests could, and perhaps should, be used in conjunction with imaging scans to better monitor patients during their follow-up period after treatment," said Charles B. Simone, II, M.D., the study's senior author and principal investigator, as well as an associate professor of radiation oncology at the University of Maryland School of Medicine and medical director of the Maryland Proton Treatment Center in Baltimore.

For more information: www.thoracicsymposium.org

Related Content

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Videos | Computed Tomography (CT) | July 19, 2019
Quynh Truong, M.D., MPH, associate professor of radio
Low Doses of Radiation Promote Cancer-capable Cells
News | Radiation Dose Management | July 18, 2019
Low doses of radiation equivalent to three computed tomography (CT) scans, which are considered safe, give cancer-...
New Lung Ambition Alliance Aims to Double Five-year Lung Cancer Survival by 2025
News | Lung Cancer | July 17, 2019
The International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (...
Example of an intentionally truncated CT image

Figure 1: Example of an intentionally truncated CT image. The truncation percentage was calculated as the ratio of the patient border touching the field of view to the total patient border (red/(read+blue)). Image courtesy of Qaelum.

Feature | Radiation Dose Management | July 15, 2019 | Niki Fitousi, Ph.D., and An Dedulle
One of the main benefits of a radiation dose management system is the possibility to automatically generate alerts when...
Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity.

Routine scan of abdomen pelvis taken with the UW-Madison’s Revolution 256 CT scanner using the FDA-cleared reconstruction algorithm, called TrueFidelity. UW-Madison was the first site in the U.S. to get this technology. Its use is now being integrated into UW CT protocols. Image courtesy of Timothy P. Szczykutowicz

Feature | Computed Tomography (CT) | July 12, 2019 | By Greg Freiherr
When providers develop their own imaging protocols, they are wasting time and money, according to...
Mednax National Cardiac Centers of Excellence Program Highlighted at SCCT 2019
News | CT Angiography (CTA) | July 11, 2019
Mednax Inc. and Mednax Radiology Solutions announced that Chief Medical Officer Ricardo C. Cury, M.D., FSCCT, will...
Achenbach to Receive Inaugural 2019 Stephan Achenbach Pioneer Award in Cardiovascular CT
News | Cardiac Imaging | July 10, 2019
The Society of Cardiovascular Computed Tomography (SCCT) will present Stephan Achenbach, M.D., FSCCT with the inaugural...